Emerging treatment options for short bowel syndrome: Potential role of teduglutide

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 189-196

  Tee, Cheng T ^a,b   Wallis, Katharina ^a,c   Gabe, Simon M ^a,d  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c WEST HERTFORDSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Glucagon like peptide 2; Intestinal adaptation; Intestinal failure; Parenteral nutrition

Indexed keywords

GATTEX; GLUCAGON LIKE PEPTIDE 2; INTERLEUKIN 10; PLACEBO; TEDUGLUTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; BLOATING; COLITIS; CONSTIPATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; ILEITIS; IMMUNOMODULATION; INJECTION SITE ERYTHEMA; LEG EDEMA; LOW DRUG DOSE; NAUSEA; NONHUMAN; OSTEOPOROSIS; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; REVIEW; RHINOPHARYNGITIS; SHORT BOWEL SYNDROME; STOMA SWELLING; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 80955136824     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S13906     Document Type: Review

References (48)

1. Pironi L, Forbes A, Joly F, et al. Survival of patients identifed as candidates for intestinal transplantation: a 3-year prospective follow-up. Gastroenterolog y. 2008;135(1):61-71.
2. Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Effect of glutamine in short-bowel syndrome. Clin Nutr. 2001;20(4):319-323.
3. Scolapio JS, Camilleri M, Fleming CR, et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterolog y. 1997;113(4):1074-1081.
4. Seguy D, Vahedi K, Kapel N, Souberbielle J-C, Messing B. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology. 2003; 124(2):293-302.
5. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut. 2000;47(2):199-205.
6. Nightingale J, Woodward JM; and Small Bowel and Nutrition Committee of the British Society of Gastroenterology. Guidelines for management of patients with a short bowel. Gut. 2006;55(Suppl 4):iv1-iv12.
7. Hornby PJ, Moore BA. The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease. Expert Opin Ther Targets. 2011;15(5):637-646.
8. Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides. 2000;21(1):73-80.
9. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol. 2003;81(11):1005-1012.
10. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275:911-921.
11. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93(15):7911-7926.
12. Burrin DG, Stoll B, Guan X, Cui L, Chang X, Holst JJ. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146(1): 22-32.
13. Koopmann MC, Nelson DW, Murali SG, et al. Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats. JPEN J Parenter Enteral Nutr. 2008;32(3):254-265.
14. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130(1):44-54.
15. Nagell C F, Wettergren A, Pedersen J F, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol. 2004;39(4): 353-358.
16. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000; 47(1):112-119.
17. Hadjiyanni I, Li KK, Drucker DJ. Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse. Endocrinology. 2009;150(2): 592-599.
18. Ivory CPA, Wallace LE, Mccafferty D-M, Sigalet DL. Interleukin-10-independent anti-infammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 2008;295(6):1202-1210.
19. Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood fow. Gastroenterolog y. 2006;130(1):150-164.
20. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology. 2000;119(3):744-755.
21. Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofbroblasts with GLP-2 receptors. Regul Pept. 2005;124(1-2): 105-112.
22. Dubé PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab. 2007; 293(2):460-465.
23. Dubé PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal trophic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131(2):589-605.
24. Bulut K, Pennartz C, Felderbauer P, et al. Glucagon like pep-tide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts. Eur J Pharmacol. 2008;578(2-3): 279-285.
25. Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-infammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):211-221.
26. Rowland KJ, Brubaker PL. The 'cryptic' mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol. 2011; 301(1):G1-G8.
27. Hartmann B, Harr MB, Jeppesen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000;85(8):2884-2888.
28. Hartmann B, Thulesen J, Kissow H, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology. 2000;141(11):4013-4020.
29. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut. 1999;45(4):559-563.
30. Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 2000;47(3):370-376.
31. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120(4): 806-815.
32. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224-1231.
33. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard J P, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7): 902-914.
34. Jeppesen PB, Messing B, Pertkiewicz M, Cyran J, Demchyshyn LL, Kershner R. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, improves fluid balance in short bowel syndrome (SBS) patients depending on parenteral support (PN). Gastroenterology. 2008;134(4): A110-A111.
35. Gilroy R, Allard J, Jeppesen PB, et al. Treatment out to 1 year with a GLP-2 analog, teduglutide, safely reduces parenteral nutrition (PN) needs in PN-dependent short bowel syndrome (SBS) patients. Am J Gastroenterol. 2008;103:S105-S106.
36. NPS Pharmaceuticals, Inc. A 24-week study of the effcacy and safety of teduglutide in subjects with parenteral nutrition-dependent short bowel syndrome. NPS press release. STEPS (Study of Teduglutide in PN-dependent Short-bowel syndrome). 2011. In press.
37. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res. 2003;18(12):2180-2189.
38. Haderslev K V, Jeppesen PB, Hartmann B, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gasterol. 2002;37(4):392-398.
39. Gottschalck IB, Jeppesen PB, Hartmann B, et al. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol. 2008;43(11):1304-1310.
40. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like peptide-2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract. 2009; 2009:616054.
41. Xiao Q, Boushey R P, Cino M, Drucker DJ, Brubaker PL. Circulating levels of glucagon-like peptide-2 in human subjects with infammatory bowel disease. Am J Physiol Regul Integr Comp Physiol. 2000;278(4): 1057-1063.
42. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; For the Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Infamm Bowel Dis. 2010;16(6): 962-973.
43. Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol. 2005; 19(2):459-473.
44. 2] GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol Gastrointest Liver Physiol. 1999;276: 79-91.
45. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ. Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res. 2008;19(2):7897-7904.
46. Rocha FG, Shen KR, Jasleen J, et al. Glucagon-like peptide-2: divergent signaling pathways. J Surg Res. 2004;121(1):5-12.
47. Iakoubov R, Lauffer LM, Trivedi S, Kim YI, Brubaker PL. Carcinogenic effects if exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology. 2009;150(9):4033-4043.
48. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut. 2004;53(8):1145-1150.